RYTM - Rhythm completes screening for Phase 3 anti-obesity study
2024-01-04 10:48:31 ET
More on Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist
- Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript
- Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Rhythm acquires rights to Phase 2 anti-obesity drug from LG Chem
- Pfizer hits new 52-week low after weight loss setback
For further details see:
Rhythm completes screening for Phase 3 anti-obesity study